anonymous
Guest
anonymous
Guest
But it's Amgen's stock that's dropping like a rock, down 7 percent post market
The stock price bounced, but still this is bad news for the BACE inhibitor Amgen is codeveloping with NovartisBut it's Amgen's stock that's dropping like a rock, down 7 percent post market
The stock price bounced, but still this is bad news for the BACE inhibitor Amgen is codeveloping with Novartis